CME in Minutes: Education in Primary Care

CME in Minutes: Education in Primary Care

Download on the App Store

CME in Minutes: Education in Primary Care episodes

  • Jeffrey B. Geske, MD / Anjali Tiku Owens, MD - Expert Cardiology Perspectives in HCM: Slowing Disease Progression With Early Diagnosis and Integration of Cardiac Myosin Inhibitors
    Please visit answersincme.com/PBR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in managing hypertrophic cardiomyopathy (HCM) discuss best practices for diagnosis and evidence-based strategies using cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Identify best practices to optimally diagnose patients with HCM in order to improve patient outcomes; Describe the clinical impact of cardiac myosin inhibitors in managing patients with obstructive HCM; and Outline practical strategies to incorporate cardiac myosin inhibitors into treatment plans for patients with obstructive HCM.
    16 min
  • Kieran McCafferty, MB BChir, MRCP, MDres - The Latest News on SGLT2 Inhibitors in Chronic Kidney Disease: Improving Outcomes With Early Intervention
    Please visit answersincme.com/CKS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses when to use SGLT2 inhibitors in patients with chronic kidney disease. Upon completion of this activity, participants should be better able to: Describe the benefits of SGLT2 inhibitor use in the management of CKD; Define strategies for the early implementation of SGLT2 inhibitor therapy in CKD; and Identify appropriate patient populations for the early implementation of SGLT2 inhibitor therapy in CKD.
    16 min
  • Peter Lio, MD - Enriching Care for Pediatric Atopic Dermatitis: Evidence-Based Strategies for Integrating Targeted Systemic Therapies
    Please visit answersincme.com/CQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology provides a comprehensive update on the evidence-based use of targeted systemic therapies in pediatric patients with moderate-to-severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when initiation of systemic therapy may be warranted in pediatric patients with moderate-to-severe atopic dermatitis (AD); Describe the clinical profiles of targeted systemic therapies that are approved for pediatric patients with moderate-to-severe AD; and Outline patient-centered strategies to enhance long-term outcomes for pediatric patients with moderate-to-severe AD who are candidates for targeted systemic therapies.
    17 min
  • David S. Boyer, MD - An Eye Toward Improving Adherence: Easing the DME Treatment Burden With Longer-Acting Anti-VEGF Agents
    Please visit answersincme.com/YYB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses strategies for selecting anti-VEGF therapy and maintaining adherence for patients with diabetic macular edema. Upon completion of this activity, participants should be better able to: Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with diabetic macular edema (DME); Review the clinical profiles of longer-acting vascular endothelial growth factor (VEGF)-targeted agents with phase 3 trial evidence in the treatment of DME; and Outline patient-centered management approaches to improve adherence to VEGF-targeted therapy.
    15 min
  • Jamie E. Chaft, MD - Enhancing Outcomes for Patients With Resected, Early-Stage NSCLC: A Piercing Evaluation of the Clinical Support for Adjuvant Immunotherapies
    Please visit answersincme.com/VET860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the use of adjuvant chemotherapy for patients with early-stage non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Describe the rationale for adjuvant immunotherapy in patients with early-stage non–small-cell lung cancer (NSCLC) following surgery and chemotherapy; Review the clinical profiles of approved and emerging adjuvant immunotherapy regimens in early-stage NSCLC; and Outline factors that optimize integration of adjuvant immunotherapy regimens for early-stage NSCLC into clinical practice.
    15 min
  • Bradley Chipps, MD - Calling the Shots for Pediatric Asthma Control: Integrating Biologics Into the Treatment Plan to Enhance Outcomes
    Please visit answersincme.com/UPM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in allergy and respiratory disease discuss patient-centered strategies to improve treatment of children with asthma. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment with biologic therapy; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate-to-severe asthma; and Outline patient-centered strategies to enhance outcomes for pediatric patients with inadequately controlled moderate-to-severe asthma.
    14 min
  • W. Lloyd Clark, MD - The Urgency of Retinal Vein Occlusion: Timely Detection, Referral, and Management
    Please visit answersincme.com/MUP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses the importance of early detection and referral of patients with retinal vein occlusion (RVO), as well as a personalized and multidisciplinary approach to management. Upon completion of this activity, participants should be better able to: Recognize the rationale for early detection of RVO; Describe the appropriate processes for timely referral of patients with RVO; and Outline strategies for personalized, multidisciplinary management of patients with RVO.
    14 min
  • Stephen Lam Chan, MD - Recalibrating Survival: Available and Recently Approved Immunotherapy-Based Combination Approaches in Unresectable HCC
    Please visit answersincme.com/TZQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in clinical oncology discusses optimizing patient outcomes with immunotherapy-based combination approaches in unresectable hepatocellular carcinoma (HCC). Upon completion of this activity, participants should be better able to: Recognize the role of available and recently approved immunotherapy-based combination regimens for the management of unresectable HCC; Outline the practical implications of the clinical trial data evaluating available and recently approved immunotherapy-based combination regimens for unresectable HCC; and Review a personalized approach to optimize patient outcomes on available and recently approved immunotherapy-based combination regimens, thus enhancing quality of life.
    14 min
  • Yasha Modi, MD / Christina Y. Weng, MD, MBA - Weighing Out the Risks and Benefits of Intravitreal Anti-VEGF Injections for nAMD
    Please visit answersincme.com/XVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss intravitreal anti–vascular endothelial growth factor (VEGF) injections for neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-vascular endothelial growth factor (anti-VEGF) therapies used in the treatment of nAMD; and Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD.
    18 min
  • Eric Jonasch, MD - Optimizing Long-Term Care With Guideline-Recommended Systemic Treatment Options for von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
    Please visit answersincme.com/XJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and urology discuss guideline-recommended systemic treatment options and strategies to optimize long-term care for patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). Upon completion of this activity, participants should be better able to: Recognize unmet needs in the management of VHL disease-associated RCC; Describe the clinical impact of current guideline-recommended systemic treatment options for VHL disease-associated RCC; and Identify strategies to optimize long-term care for patients with VHL disease-associated RCC.
    14 min

About CME in Minutes: Education in Primary Care

From the publisher's feed

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Primary Care by Answers in CME. Benefit from digests of latest advancements,…

More shows like CME in Minutes: Education in Primary Care

CME in Minutes: Education in Dermatology by Answers in CME

CME in Minutes: Education in Dermatology

3 Listeners

CME in Minutes: Education in Oncology & Hematology by Answers in CME

CME in Minutes: Education in Oncology & Hematology

7 Listeners

CME in Minutes: Education in Ophthalmology by Answers in CME

CME in Minutes: Education in Ophthalmology

2 Listeners

CME in Minutes: Education in Cardiology & Pulmonology by Answers in CME

CME in Minutes: Education in Cardiology & Pulmonology

3 Listeners

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases by Answers in CME

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

4 Listeners